Kraig Biocraft Laboratories, Inc. Receives New Custom Zinc Finger Configurations for Advanced Fibers Development

LANSING, MI--(Marketwire - December 12, 2011) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (PINKSHEETS: KBLB) announced that the Company has taken delivery, from Sigma-Aldrich, of newly created zinc finger nuclease configurations. These zinc fingers were created per the Company’s requirements pursuant to the Company’s license agreement with Sigma-Aldrich. These zinc fingers were specifically designed to enable Kraig Biocraft Laboratories to produce advanced fibers and textiles based on spider silk genetic sequences.

Zinc fingers are a gene splicing technology which Kraig Biocraft Laboratories has recently used to create seven new strains of transgenic silkworm. The customized zinc fingers, which are being announced today, are a new configuration that has been specifically tailored for the creation of the Company’s second generation advanced fibers and technical textiles program.

“We have designed specific genetic constructs which are the blueprints for a revolutionary spider silk polymer,” said Company founder and CEO, Kim K Thompson. “The new ZFN tools have been created for us by Sigma-Aldrich for the specific purpose of helping us move from the blueprints to the actual production of this exciting material.”

“While we remain excited about the commercial prospects for our current generation of recombinant spider silk based polymers, there is no question that the fibers that these zinc fingers were designed to help create are much more advanced,” continued Thompson. “We believe that this second generation technology has the potential to open up entirely new markets.”

The Company is already gearing up to perform the genetic splices with the new technology. “Our experience with the first ZFN configurations over the summer was incredibly positive,” said Thompson. “We were able to achieve a much higher success rate with our first gene splices than we anticipated, resulting in the creation of seven new strains of transgenics,” Thompson continued. “If these new configurations work even half as well, we can expect the very advanced fibers that we have designed to become a very exciting tangible reality.”

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “develops,” “researching,” “research,” “potential,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.